Page last updated: 2024-09-03

gefitinib and Neoplasms

gefitinib has been researched along with Neoplasms in 252 studies

Research

Studies (252)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's157 (62.30)29.6817
2010's81 (32.14)24.3611
2020's14 (5.56)2.80

Authors

AuthorsStudies
Ballard, P; Bradbury, RH; Harris, CS; Hennequin, LF; Hickinson, M; Kendrew, J; Kettle, JG; Klinowska, T; Ogilvie, DJ; Pearson, SE; Williams, EJ; Wilson, I1
Chandrasekara Reddy, G; Chandregowda, V; Kush, AK1
Bikker, JA; Brooijmans, N; Mansour, TS; Wissner, A1
Chen, X; Chen, Y; Gao, C; Jiang, Y; Li, Y; Liu, H; Luan, X; Tan, C; Zhang, C1
Dubey, PK; Pal, M; Piedrafita, FJ; Rajitha, C; Sunku, V; Veeramaneni, VR1
Ai, J; Chen, Y; Geng, M; Jiang, H; Li, C; Liang, Z; Liu, H; Luo, C; Wang, Y; Zhai, Y; Zhang, D; Zhang, X; Zhao, F1
Luo, ZL; Qiu, HY; Wang, PF; Wang, SF; Yang, YA; Yin, Y; Yuan, JW; Zhang, F; Zhang, X; Zhu, HL1
Dong, H; Li, J; Ouyang, L; Song, S; Xu, C; Zhang, H1
Cao, HQ; Chu, MJ; Li, QS; Liu, DH; Lv, XH; Mo, K; Ren, ZL; Yao, XK; Zhang, LS; Zhou, BG1
Abadi, AH; Darwish, SS; Engel, M; Hamed, MM; Herrmann, J1
Abouzid, KAM; Lasheen, DS; Milik, SN; Serya, RAT1
Cao, YX; Hei, YY; Li, Y; Shen, Y; Wang, J; Xin, M; Zhang, H; Zhang, SQ; Zhao, HY1
Abbas, SY; Ammar, YA; Belal, A; Mehany, ABM; Mohamed, YA; Ragab, A; Sh El-Sharief, AM1
Cheng, H; Deng, M; Ding, Z; Dou, G; Hou, Y; Li, F; Li, W; Ma, M; Zhao, J1
Chen, LZ; Kong, FL; Lu, YD; Shen, FQ; Wang, MH; Wang, ZC; Yang, MR; You, LX; Zhu, HL1
Mathias, F; Montana, M; Terme, T; Vanelle, P1
Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q1
Abdel-Maksoud, MS; Ali, EMH; Oh, CH1
Das, D; Hong, J1
Azad, R; Deshmukh, TR; Lokwani, DK; Sarkate, AP; Shingate, BB; Tiwari, SV1
Dehaen, W; Li, Y; Wang, R1
Bansal, R; Malhotra, A1
Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W1
Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F1
Karimi, Z; Minaiyan, M; Mirian, M; Taymouri, S1
Abdellatif, AAH; Al-Subaiyel, A; Mohammed, AM1
Choe, J; Guo, S; Han, H; Lin, S; Liu, L; Ma, J; Wang, J; Wang, L; Wang, X; Wang, Z; Wei, W; Yang, C; Zhang, S; Zheng, S1
Ding, T; Guo, N; Jiang, L; Ma, J; Shao, L; Song, D; Wang, J; Yan, L; Zhai, W; Zhang, W; Zhao, F1
Edeline, J; Frenel, JS; Gilabert, M; Raoul, JL; Senellart, H1
Deshmukh, PK; More, MP1
Byeon, S; Hong, JY; Kang, WK; Kim, ST; Lee, J; Lim, HY; Nam, DH; Park, JO; Park, SH; Park, YS1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z1
Bria, E; Cintoni, M; Gasbarrini, A; Mele, MC; Pompili, M; Ponziani, FR; Pozzo, C; Raoul, P; Rinninella, E; Strippoli, A; Tortora, G1
Fu, J; Gao, J; Han, S; Jia, Q; Liang, P; Lv, Y; Wang, S; Yi, X; Zhang, L; Zhou, H1
Bae, JH; Baek, MC; Cho, SY; Cho, Y; Choi, YJ; Jeong, SB; Jun, DW; Kang, KW; Kang, S; Kim, JK; Kim, JW; Kim, KM; Kim, W; Kim, Y; Lee, H; Lee, SH; Lim, SC; Park, M1
Boeck, S; Heinemann, V; Hichert, V; Kächele, V; Paul, T; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Steffens, M; Stingl, J1
Shi, Y; Su, C; Zhao, L; Zheng, Y1
Hughes, MP; Labeed, FH; Mahabadi, S1
Chen, X; Chen, Y; Du, Y; Guo, Y; Li, W; Wang, J; Wang, X; Wu, M; Wu, Z; Yan, X; Yang, F; Zhou, L1
Carbone, ML; Lulli, D; Passarelli, F; Pastore, S1
Ali, R; Brown, W; Davisson, VJ; Purdy, SC; Wendt, MK1
An, T; Deng, X; Hu, C; Jin, Z; Ma, Q; Meng, Q; Tan, X; Wang, C1
Hemler, ME; Hwang, S; Takimoto, T1
Fujiwara, M; Furuse, J; Goto, H; Goya, T; Hiraoka, S; Ishii, H; Saraya, T; Takizawa, H; Tamura, M; Yano, K; Yokoyama, T1
Asano, H; Gazdar, AF; Hashida, S; Ichihara, E; Jida, M; Kiura, K; Lam, WL; Maki, Y; Miyoshi, S; Shien, K; Soh, J; Takigawa, N; Thu, KL; Toyooka, S; Tsukuda, K; Yamamoto, H1
Ashworth, A; Campbell, J; Herrera-Abreu, MT; Knowles, MA; Pearson, A; Shnyder, SD; Turner, NC1
He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y1
Fung, AS; Tannock, IF; Ye, QJ; Yu, M1
Baradia, D; Misra, A; Patil, S; Vhora, I; Yewale, C1
Day, RO; Kerridge, IH; Lewis, JR; Lipworth, WL1
Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY1
Dosaka-Akita, H; Hirata, K; Kuge, Y; Shiga, T; Takei, T; Takeuchi, S; Tamaki, N; Zhao, S; Zhao, Y1
Jia, B; Liu, H; Liu, Z; Ma, T; Shi, J; Sun, X; Wang, F; Zhao, H1
Eisenstein, M2
Brennan, RC; Furman, W; Mao, S; McGregor, LM; Santana, V; Stewart, CF; Turner, DC; Wu, J1
Dastgheib, S; Kannan, N; Katiyar, S; Kochut, K; McSkimming, DI; Narayanan, A; Talevich, E; Taylor, SS1
Anderson, KS; Apetri, M; Kim, Y; Luo, B; Settleman, JE1
Jean-Claude, BJ; Larroque-Lombard, AL; Peyrard, L; Rachid, Z; Rao, S; Thauvin, C; Williams, C1
Chariot, A; Shostak, K1
Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W1
Blagg, J; Boxall, K; Burke, R; Cheung, KM; Faisal, A; Gurden, MD; Hoelder, S; Linardopoulos, S; Mak, G; McAndrew, C; Naud, S; Schmitt, J; Van Montfort, RL; Westwood, IM; Wood, A; Workman, P1
Nishio, K; Togashi, Y1
Cosmai, L; Gallieni, M; Porta, C1
Cameron, MG; Kersten, C; Laird, B; Mjåland, S1
Chen, Y; Ding, J; Geng, M; Huang, M; Shen, A; Shen, YY; Sun, J; Wang, L; Wang, X; Yang, X1
An, G; Bi, Y; Deng, J; Murry, DJ1
Feng, B; Liu, M; Shi, Y; Su, C; Yang, G; Yu, X; Zhao, L1
Bagadi, M; Binda, MM; Chaltin, P; Daniels, VW; Dehairs, J; Khan, NA; Marchand, A; Munck, S; Rueda-Rincon, N; Swinnen, JV; Talebi, A; Thimiri Govinda Raj, DB; Vanderhoydonc, F; Willemarck, N1
Doi, T; Enatsu, S; Kojima, T; Nakamura, T; Ohmatsu, H; Takahashi, H; Turner, K; Uenaka, K; Wacheck, V; Yoh, K; Zenke, Y1
Ding, Q; Li, H; Li, J; Wang, S; Wang, Y; Xia, J; Ye, P; Zhang, Y1
Beck, S; Frejno, M; Klaeger, S; Koch, H; Kuster, B; Ruprecht, B; Wilhelm, M1
Erbacher, I; Gotham, D; Harada, R; Hill, A; Meldrum, J; Redd, C1
Greene, MI; Wang, Q1
Gemma, A; Noro, R1
Bourhis, J; Castadot, P; Chargari, C; Deutsch, E; Ghalibafian, M; Haie-Meder, C; Magné, N; Soria, JC1
Bianco, R; Del Vecchio, S; Fonti, R; Iommelli, F; Lettieri, A; Papaccioli, A; Pirozzi, G; Salvatore, M; Sommella, J; Tortora, G; Zannetti, A1
Ferlini, C; Mozzetti, S; Riccardi, A; Riccardi, R; Servidei, T1
Abbott, A1
Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N1
Andersen, P; Poulsen, HS; Stockhausen, MT; Villingshøj, M1
Dreyer, C; Faivre, S; Raymond, E1
Christy, R; Engler, KL; Fakih, MG; Johnson, CS; Muindi, JR; Trump, DL1
Katayama, K; Mitsuhashi, J; Noguchi, K; Shibata, K; Sugimoto, Y1
Gotoh, N; Hatanaka, Y; Higuchi, T; Imoto, S; Miyano, S; Nagasaki, M; Shimamura, T; Ueno, K; Yamaguchi, R; Yamauchi, M; Yoshida, R1
Chen, P; Chen, ZG; Du, Y; Fu, H; Khuri, FR; Li, L; Li, Z; Shin, DM; Sun, SY1
Crews, KR; Daw, NC; Furman, WL; Gajjar, AJ; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Spunt, SL; Stewart, CF; Wu, J1
Wang, CL; Wang, J; Wang, P; Yuan, ZY; Zhao, LJ; Zhuang, HQ1
Ishikawa, T; Nakagawa, H1
Ito, F; Takeuchi, K1
Carter, CA; Giaccone, G; Kelly, RJ1
Mintz, A; Nguyen, V1
Giaccone, G; Hoekman, K; Jürgensmeier, JM; Meijerink, MR; Puchalski, TA; Punt, CJ; Robertson, J; Saunders, O; van Cruijsen, H; van Herpen, CM; Voest, EE; Witteveen, PO1
Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A1
Burenkova, O; Crosby, K; Engelman, JA; Faber, AC; Fulgham, A; Li, D; Liang, MC; Nie, L; Nielsen, UB; Onsum, M; Pace, E; Schoeberl, B; Song, Y; Walton, Z; Wong, KK1
Harris, TJ; McCormick, F1
Dunn, EF; Harari, PM; Wheeler, DL1
Allen, JW; Daw, NC; Furman, WL; Geyer, JR; McGregor, LM; McKibbin, T; Stewart, CF; Tagen, M; Zhao, W1
Haramoto, M; Horibe, T; Kawakami, K; Kohno, M; Matsuzaki, K; Nakajima, O; Ohara, K; Yano, Y1
Katsifis, A; Lin, HQ; Meriaty, H1
Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N1
Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V1
Doussau, A; Le Tourneau, C; Ollivier, L; Paoletti, X; Postel-Vinay, S; Servois, V1
Curtit, E; Mansi, L; Viel, E; Vignot, S1
Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA1
Agus, DB; Gross, ME; Leichman, L; Lowe, ES; Swaisland, A1
Tolcher, AW1
Coffey, RJ; Liebler, DC; Manning, HC; Myers, MV1
Boeck, S; Heinemann, V; Kächele, V; Parmar, S; Paul, T; Rüdiger, S; Schumann, C; Seeringer, A; Seufferlein, T; Stingl, JC1
Chen, X; Feng, S; Ji, P; Li, LL; Luo, SD; Ma, S; Pan, YL; Wang, ZR; Wei, YQ; Yang, SY; Zhong, L; Zhou, JP1
Barni, S; Borgonovo, K; Cabiddu, M; Petrelli, F1
Daw, HA; Peerzada, MM; Spiro, TP1
Arkhipov, A; Dror, RO; Eastwood, MP; Jumper, J; Kim, ET; Kuriyan, J; Shan, Y; Shaw, DE; Zhang, X1
Balu-Iyer, SV; Iyer, V; O'Connor, R; Straubinger, RM; Trummer, BJ1
Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ1
Basti, S; Borkar, DS; Lacouture, ME1
Wakeling, AE1
Baselga, J3
Ranson, M1
Arteaga, CL1
Averbuch, SD; Baselga, J; Herbst, RS; Hong, WK; LoRusso, PM; Maddox, AM; Ochs, J; Rojo, F; Rothenberg, ML; Rubin, EH; Small, EJ; Swaisland, H1
Couzin, J1
Rowinsky, EK; Takimoto, CH; Tolcher, AW1
Garber, K2
Baldwin, J1
Workman, P1
Albanell, J; Baselga, J1
Fischman, J1
Bianco, C; Ciardiello, F; Harari, P; Helfrich, B; Raben, D; Weng, E1
Bianco, C; De Luca, A; Maiello, MR; Normanno, N; Salomon, DS1
Schultz, J1
Giaccone, G; Lobbezoo, MW; Van Kalken, C1
Dong, RP; Fukuoka, M; Hirose, M; Kudoh, S; Nakagawa, K; Nakatani, I; Negoro, S; Swaisland, H; Takeda, K; Tamura, T; Yamamoto, N1
Grünwald, V; Hidalgo, M1
Dufresne, A; Gainet, M; Guardiola, E; Pivot, X1
George, SL1
Chen, J; Haimovitz-Friedman, A; Kris, MG; Lee, F; Miller, VA; Rusch, VR; She, Y; Sirotnak, FM1
Goldman, B1
Averbuch, SD1
Fayette, J; Soria, JC1
Shiotsu, Y1
Giaccone, G; Janmaat, ML1
Ciardiello, F; De Placido, S; De Vita, F; Orditura, M; Tortora, G1
Mikami, O; Tsukagoshi, S1
Pérez-Soler, R1
Gray, ML; Khan, S; Zimmerman, R1
Azria, D; Culine, S; Dubois, JB; Larbouret, C; Pèlegrin, A; Robert, B; Verrelle, P; Ychou, M1
Ochs, JS1
Kim, R; Toge, T1
Grandis, JR; Thomas, SM1
Hu, B; Wei, YQ1
Krozely, P1
Alfonso, R; Averbuch, S; Fandi, A; Giaccone, G; González-Larriba, JL; Martens, M; Peters, GJ; Smit, EF; Smith, R; van der Vijgh, WJ; van Oosterom, AT1
Marmé, D1
Broxterman, HJ; Georgopapadakou, NH1
Cavanaugh, SX; Hammond, LA; Thomas, CR1
Blagosklonny, MV1
Castillo, L; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Magné, N; Milano, G1
Capriotti, T1
El-Rayes, BF; LoRusso, PM1
Druker, BJ1
Bessis, D; Fabbro, M; Guillot, B; Jacot, W; Jorda, E; Pujol, JL; Ychou, M1
Uehara, Y1
Akiyama, S2
Barthorpe, A; Bignell, G; Blow, M; Brackenbury, L; Brasseur, F; Butler, A; Chenevix-Trench, G; Clarke, O; Cole, J; Cooper, CS; Davies, H; Dicks, E; Dike, A; Drozd, A; Edkins, S; Edwards, K; Flanagan, AM; Forbes, S; Foster, R; Futreal, PA; Goldstraw, P; Gray, K; Greenman, C; Halliday, K; Harris, G; Hills, K; Hunter, C; Knowles, M; Kosmidou, V; Leung, SY; Looijenga, LH; Louis, DN; Lugg, R; Malkowicz, B; Menzies, A; Nicholson, AG; O'Meara, S; Parker, A; Perry, J; Petty, R; Pierotti, MA; Raine, K; Ratford, L; Shepherd, R; Small, A; Smith, R; Stephens, P; Stephens, Y; Stevens, C; Stratton, MR; Teague, J; Teh, B; Tofts, C; Varian, J; Weber, BL; West, S; Widaa, S; Wooster, R; Yates, A; Yuen, ST1
Ginsburg, GS; Hortobagyi, GN; Linette, GP; Pietrusko, R; Pusztai, L; Rolfe, M; Ross, JS; Schenkein, DP; Stagliano, NE; Stec, J; Symmans, WF1
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P1
Von Pawel, J1
Arao, T; Fukumoto, H; Nishio, K; Saijo, N; Takeda, M; Tamura, T1
Harari, PM1
Favaudon, V; Hennequin, C1
Attard, G; De Bono, J; Kaye, S; Vidal, L1
Batist, G; Douglas, L; Friedmann, J; Goss, G; Hanna, P; Hirte, H; Lorimer, IA; Mathews, S; Miller, WH; Parolin, DA; Seymour, LK; Stafford, S; Stewart, D; Walsh, W1
Barnett, S; Bichat, F; Giles, PB; Guilbaud, N; Kemp, JV; Kendrew, J; McKillop, D; Partridge, EA; Patterson, AB; Spence, MP; Stephens, TC; Wood, PG1
Albanell, J; Gascón, P1
Blum, HE; Geissler, M; Grimm, CF1
Barrow, D; Gee, JM; Jones, HE; Nicholson, RI; Rubini, M; Taylor, KM; Williams, HD1
Adamson, PC; Bernstein, ML; Blaney, SM; Croop, JM; Dancey, JE; Daw, NC; Furman, WL; Iacono, LC; Krailo, M; Reaman, GH; Speights, RA; Stewart, CF1
Arnold, D; Mueller, T; Pfeiffer, C; Pickan, V; Simon, H; Voigt, W1
Lawrence, TS1
Laight, A; Leadbetter, J; McKillop, D; Ranson, M; Smith, RP; Swaisland, HC; Wild, MJ1
Elsner, J; Gutzmer, R; Kapp, A; Werfel, T1
Frantz, S1
Bates, SE; Fojo, T1
Herbst, RS; Kies, MS1
Ciardiello, F; De Vita, F1
Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F1
Jacobson, JW; Lively, TG; Taube, SE1
Adamson, P; Amador, ML; Blaney, SM; Cusatis, G; Daw, NC; Hidalgo, M; Ingle, AM; Jimeno, A; Krailo, M; Kulesza, P1
Sun, Y; Wang, Y1
Bouaroud, N; Brahmer, J; Chan, A; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P1
Ashworth, A; Caplin, M; Friedmann, BJ; Hartley, JA; Hochhauser, D; Lord, CJ; Savic, B; Shah, T1
Bartolini, S; Cancellieri, A; Cappuzzo, F; Castaldini, L; Crino, L; Finocchiaro, G; Magrini, E; Metro, G; Tallini, G; Trisolini, R1
Amino, N; Hisamichi, H; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M1
Schwartz, LM; Woloshin, S1
Fish-Steagall, A; Searcy, P; Sipples, R1
Sipples, R1
Amann, K; Fässler, R; Ferby, I; Klein, R; Knyazev, P; Kraut, N; Kudlacek, O; Pantè, G; Reschke, M; Sommergruber, W; Ullrich, A1
Katoh, M; Katoh, Y1
Gao, M; Miller, KD; Sledge, GW; Wang, JQ; Zheng, QH1
Million, RP1
Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN1
Bremer, E; de Leij, L; Helfrich, W; Kroesen, BJ; van Dam, G1
Pedersen, MW; Poulsen, HS1
Kudoh, S; Yoshimura, A1
Ichinose, Y; Maehara, Y; Oda, S; Okamoto, T; Yamanaka, T1
Baselga, J; Mendelsohn, J2
Azzoli, CG; Fury, MG; Gomez, JE; Henry, R; Kris, MG; Miller, VA; Pfister, DG; Pizzo, BA; Rizvi, NA; Rosen, N; Sirotnak, FM; Smith, RP; Solit, DB; Su, YB1
Morse, L1
Curtiss, FR1
Arslan, MA; Basaga, H; Kutuk, O1
Baker, SD; Brahmer, J; Hidalgo, M; Karlsson, MO; Li, J; Spitz, A; Zhao, M1
Baker, SD; Cusatis, G; Gregorc, V; Hidalgo, M; Ingersoll, RG; Li, J; Ludovini, V; Sparreboom, A; Spreafico, A; Verweij, J; Villa, E1
Barrow, D; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; Nicholson, RI2
Nakagawa, K2
Baker, SD; Bates, SE; Brahmer, J; Cusatis, G; Hidalgo, M; Li, J; Robey, RW; Sparreboom, A1
Bernardi, RJ; Black, JD; Brattain, MG; Creaven, PJ; Fakih, MG; French, R; Hutson, A; Johnson, CS; Muindi, JR; Schwartz, J; Trump, DL1
Dutta, PR; Maity, A1
Chen, Z; Gonzalez, KD; Gu, D; Hill, KA; Li, K; Saldivar, JS; Scaringe, WA; Sommer, SS1
Ang, BK; Chen, Y; Choong, LY; Druker, BJ; Hew, CL; Li, B; Lim, S; Lim, YP; Lin, Q; Low, TY; Ray, RS; Sze, NS; Tan, YL; Toy, W; Wong, CH1
Banerjee, S; Chellappan, S; Rastogi, S; Simon, GR1
Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, XX; Robey, RW; Shen, T; Shi, Z; Shukla, S; Si, QS1
Carroll, KJ; Ellis, S; Pemberton, K1
Becker, JC; Schrama, D; Ugurel, S1
Bodenstein, C; Czernin, J; Dubinett, SM; Ferl, GZ; Fueger, B; Hsu, YT; Kim, KJ; Phelps, ME; Seimbille, Y; Su, H; Weber, WA1
Giordano, S; Petrelli, A1
Bianco, R; Ciardiello, F; Damiano, V; Daniele, G; Garofalo, S; Gelardi, T; Marciano, R; Rosa, R; Tortora, G1
de Gruijl, TD; Giaccone, G; Hoekman, K; Kuenen, BC; Scheper, RJ; Stam, AG; van Cruijsen, H; van den Eertwegh, AJ1
Heymann, WR1
Fojo, T1
Ciardiello, F1
Chabner, BA; Ryan, PD1
Adi Vago, N; Armand, JP; Faivre, S; Le Chevalier, T; Meric, JB; Monnerat, C; Raymond, E1
Kuwano, M; Ono, M1
Dancey, JE; Schoenfeldt, M1
Ciardiello, F; Tortora, G1
Arteaga, CL; Johnson, DH1
Harari, PM; Huang, SM1
Albanell, J; Averbuch, S; Baselga, J; Feyereislova, A; Gee, J; Herbst, R; LoRusso, P; Mascaro, JM; Nicholson, RI; Rischin, D; Rojo, F; Sauleda, S1
Ao, Y; Fukumoto, H; Kuroki, T; Mori, M; Naruse, I; Nishio, K; Ohmori, T; Saijo, N1
Averbuch, S; Ferry, D; Feyereislova, A; Hammond, LA; Kris, M; Miller, V; Morris, C; Murray, PI; Ochs, J; Ranson, M; Rowinsky, EK; Swaisland, H; Tullo, A1
Herbst, RS1

Reviews

97 review(s) available for gefitinib and Neoplasms

ArticleYear
How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
    European journal of medicinal chemistry, 2017, Dec-15, Volume: 142

    Topics: Animals; Antineoplastic Agents; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gene Amplification; Humans; Models, Molecular; Neoplasms; Point Mutation; Protein Domains; Protein Kinase Inhibitors; Receptor, ErbB-2

2017
Antitumoral activity of quinoxaline derivatives: A systematic review.
    European journal of medicinal chemistry, 2019, Feb-01, Volume: 163

    Topics: Antineoplastic Agents; Humans; Neoplasms; Quinoxalines

2019
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
    Bioorganic & medicinal chemistry, 2019, 02-01, Volume: 27, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines

2019
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
    Bioorganic & medicinal chemistry, 2019, 04-01, Volume: 27, Issue:7

    Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Chemistry, Pharmaceutical; Humans; Inflammation; Neoplasms; Pyrimidines; Structure-Activity Relationship

2019
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
    European journal of medicinal chemistry, 2019, May-15, Volume: 170

    Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2019
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
    European journal of medicinal chemistry, 2021, Feb-05, Volume: 211

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines

2021
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
    European journal of medicinal chemistry, 2021, Mar-15, Volume: 214

    Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration

2021
[Proton pump inhibitors and cancers: A hazardous association?]
    Bulletin du cancer, 2020, Volume: 107, Issue:4

    Topics: Antineoplastic Agents; Bacterial Infections; Capecitabine; Contraindications, Drug; Drug Interactions; Dysbiosis; Erlotinib Hydrochloride; Fractures, Bone; Gastrointestinal Absorption; Gastrointestinal Neoplasms; Gefitinib; Humans; Indazoles; Kidney; Neoplasms; Prognosis; Protein-Tyrosine Kinases; Proton Pump Inhibitors; Pyrimidines; Sulfonamides

2020
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus

2016
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.
    Internal and emergency medicine, 2021, Volume: 16, Issue:5

    Topics: Gefitinib; Humans; Imatinib Mesylate; Indazoles; Muscle, Skeletal; Neoplasms; Phenylurea Compounds; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis

2021
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
    Respiratory medicine, 2013, Volume: 107, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors

2013
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Biomaterials, 2013, Volume: 34, Issue:34

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines

2013
EGFR and NF-κB: partners in cancer.
    Trends in molecular medicine, 2015, Volume: 21, Issue:6

    Topics: Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hyaluronoglucosaminidase; Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proteins; Quinazolines; Signal Transduction

2015
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
    Future oncology (London, England), 2015, Volume: 11, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases

2015
[Kinase inhibitors and their resistance].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib

2015
Renal toxicity of anticancer agents targeting HER2 and EGFR.
    Journal of nephrology, 2015, Volume: 28, Issue:6

    Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab

2015
The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:15

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome

2008
[Targeted therapies and their indications in solid neoplasias].
    La Revue de medecine interne, 2009, Volume: 30, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2009
Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
    Journal of experimental therapeutics & oncology, 2009, Volume: 8, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cyclin-Dependent Kinases; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Quantitative Structure-Activity Relationship; Quinazolines

2009
EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.
    The FEBS journal, 2010, Volume: 277, Issue:2

    Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-Associated Death Protein; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines

2010
Small-molecule inhibitors of the human epidermal receptor family.
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:12

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2009
[Cutaneous side effects of EGFR inhibitors--appearance and management].
    Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:4

    Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines

2010
The molecular pathology of cancer.
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:5

    Topics: Adenocarcinoma; Base Sequence; Breast Neoplasms; Female; Gefitinib; Genes, ras; Genome-Wide Association Study; Humans; Male; Mutation; Neoplasms; Nervous System Neoplasms; Pathology, Molecular; Quinazolines; Signal Transduction

2010
Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome

2010
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
    Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction

2011
[Dose finding methods for targeted agents: new perspectives].
    Bulletin du cancer, 2010, Volume: 97, Issue:12

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic

2010
[EGFR/HER1: a target life].
    Bulletin du cancer, 2012, Feb-01, Volume: 99, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins

2012
The evolution of phase I trials in cancer medicine: a critical review of the last decade.
    Chinese journal of cancer, 2011, Volume: 30, Issue:12

    Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Phthalazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines

2011
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arterial Occlusive Diseases; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Neoplasms; Panitumumab; Quinazolines; Randomized Controlled Trials as Topic; Risk; Venous Thromboembolism

2012
Pulmonary toxicities of tyrosine kinase inhibitors.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:11

    Topics: Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines

2011
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Current topics in medicinal chemistry, 2012, Volume: 12, Issue:15

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome

2012
Epidermal growth factor receptor tyrosine kinase inhibitors.
    Current opinion in pharmacology, 2002, Volume: 2, Issue:4

    Topics: Animals; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines

2002
Why the epidermal growth factor receptor? The rationale for cancer therapy.
    The oncologist, 2002, Volume: 7 Suppl 4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Signal Transduction

2002
ZD1839 (Iressa): for more than just non-small cell lung cancer.
    The oncologist, 2002, Volume: 7 Suppl 4

    Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome

2002
Epidermal growth factor receptor dependence in human tumors: more than just expression?
    The oncologist, 2002, Volume: 7 Suppl 4

    Topics: Antinematodal Agents; Dimerization; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Ligands; Mutation; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Signal Transduction

2002
Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Gefitinib; Genetic Therapy; Genome, Human; Humans; Imatinib Mesylate; Neoplasms; Oncogenes; Piperazines; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab

2002
Epithelial growth factor receptor interacting agents.
    Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays

2002
Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction

2002
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
    Endocrine-related cancer, 2003, Volume: 10, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab

2003
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
    Journal of the National Cancer Institute, 2003, Jun-18, Volume: 95, Issue:12

    Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship

2003
[Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2003, Volume: 7, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Cell Transformation, Neoplastic; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Survival Analysis; Treatment Outcome

2003
The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.
    Clinical lung cancer, 2003, Volume: 5 Suppl 1

    Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Quinazolines; Signal Transduction; Tumor Cells, Cultured

2003
[Current screening for molecular target therapy of cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib

2003
Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
    The oncologist, 2003, Volume: 8, Issue:6

    Topics: Cell Differentiation; Cell Movement; Cell Survival; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; History, Modern 1601-; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines

2003
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
    Expert opinion on emerging drugs, 2003, Volume: 8, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines

2003
[Development of novel molecular targeted drug, "Iressa", for the treatment of malignant diseases--its basic and clinical studies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:13

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Male; Neoplasms; Quinazolines; Rats

2003
HER1/EGFR targeting: refining the strategy.
    The oncologist, 2004, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction

2004
[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
    Bulletin du cancer, 2003, Volume: 90 Spec No

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab

2003
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
    International journal of radiation oncology, biology, physics, 2004, Mar-01, Volume: 58, Issue:3

    Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents

2004
Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
    Surgery today, 2004, Volume: 34, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Molecular Biology; Neoplasms; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab

2004
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.
    Cancer treatment reviews, 2004, Volume: 30, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Availability; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Infusions, Intravenous; Neoplasms; Quinazolines

2004
[Tumor biotherapy based on epidermal growth factor receptor as a target].
    Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:4

    Topics: Antibodies, Monoclonal; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Vaccines, DNA

2004
Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
    Clinical journal of oncology nursing, 2004, Volume: 8, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Quinazolines

2004
Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers.
    Cancer biology & therapy, 2004, Volume: 3, Issue:5

    Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Genes, abl; Humans; Neoplasms; Quinazolines

2004
Pharmacological background of EGFR targeting.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2004
New oncology strategy: molecular targeting of cancer cells.
    Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 2004, Volume: 13, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cetuximab; Cysteine Endopeptidases; ErbB Receptors; Gefitinib; Genetics, Medical; Humans; Medical Oncology; Molecular Biology; Multienzyme Complexes; Neoplasms; Neovascularization, Pathologic; Nurse's Role; Oncology Nursing; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A

2004
Targeting the epidermal growth factor receptor.
    British journal of cancer, 2004, Aug-02, Volume: 91, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines

2004
[The mechanisms of the resistance to molecular targeting agents].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Drug Delivery Systems; Drug Resistance, Neoplasm; Gefitinib; Humans; Imatinib Mesylate; In Vitro Techniques; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Trastuzumab

2004
Targeted therapies for cancer 2004.
    American journal of clinical pathology, 2004, Volume: 122, Issue:4

    Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Bevacizumab; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gemtuzumab; Humans; Neoplasms; Pharmacogenetics; Quinazolines; Rituximab; Trastuzumab

2004
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Bulletin du cancer, 2004, May-01, Volume: 91, Issue:5

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines

2004
Epidermal growth factor receptor inhibition strategies in oncology.
    Endocrine-related cancer, 2004, Volume: 11, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines

2004
Reversing resistance to targeted therapy.
    Journal of chemotherapy (Florence, Italy), 2004, Volume: 16 Suppl 4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Imatinib Mesylate; Male; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Risk Assessment; Sensitivity and Specificity; Trastuzumab

2004
[Molecular target therapy for malignant tumors].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2005, Feb-20, Volume: 94 Suppl

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; ErbB Receptors; Fusion Proteins, bcr-abl; Gefitinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Trastuzumab; Tretinoin

2005
Small molecules with EGFR-TK inhibitor activity.
    Current drug targets, 2005, Volume: 6, Issue:3

    Topics: Aminoquinolines; Aniline Compounds; Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Mutation; Neoplasms; Organic Chemicals; Quinazolines; Signal Transduction

2005
[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Deutsche medizinische Wochenschrift (1946), 2005, Jun-10, Volume: 130, Issue:23

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, abl; Humans; Imatinib Mesylate; Neoplasms; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A

2005
Development of strategies for the use of anti-growth factor treatments.
    Endocrine-related cancer, 2005, Volume: 12 Suppl 1

    Topics: Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2005
Gefitinib: current and future status in cancer therapy.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:8

    Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Signal Transduction

2003
Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
    Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 2005, Volume: 63

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines

2005
[Genetic alterations and chemoresistance].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:12

    Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzamides; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines; Thymidylate Synthase; Xeroderma Pigmentosum Group D Protein

2005
[Antineoplastic agents targeting tyrosine kinases].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, Nov-17, Volume: 125, Issue:22

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab

2005
Cancer diagnostics: decision criteria for marker utilization in the clinic.
    American journal of pharmacogenomics : genomics-related research in drug development and clinical practice, 2005, Volume: 5, Issue:6

    Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow Examination; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms; Neoplastic Cells, Circulating; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Technology Assessment, Biomedical; Trastuzumab

2005
Clinical experience with gefitinib: an update.
    Critical reviews in oncology/hematology, 2006, Volume: 58, Issue:1

    Topics: Clinical Trials as Topic; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2006
Clinical experience with anti-EGFR therapy.
    Seminars in oncology nursing, 2006, Volume: 22, Issue:1 Suppl 1

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome

2006
Common side effects of anti-EGFR therapy: acneform rash.
    Seminars in oncology nursing, 2006, Volume: 22, Issue:1 Suppl 1

    Topics: Acneiform Eruptions; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Nurse's Role; Oncology Nursing; Patient Education as Topic; Quinazolines; Severity of Illness Index

2006
[Problems in the current target therapy of malignancies].
    Voprosy onkologii, 2005, Volume: 51, Issue:5

    Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab

2005
Targeted induction of apoptosis for cancer therapy: current progress and prospects.
    Trends in molecular medicine, 2006, Volume: 12, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Galectins; Gefitinib; Humans; Models, Biological; Neoplasms; Quinazolines; Rituximab; Signal Transduction

2006
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
    Ugeskrift for laeger, 2006, Jun-12, Volume: 168, Issue:24

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Neoplasms; Prognosis; Quinazolines; Receptor Protein-Tyrosine Kinases

2006
[Current status and problems of anticancer drug-induced lung injuries].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Antineoplastic Agents; Diagnosis, Differential; Gefitinib; Humans; Lung Diseases, Interstitial; Neoplasms; Product Surveillance, Postmarketing; Quinazolines; Risk Factors

2006
Methodological aspects of current problems in target-based anticancer drug development.
    International journal of clinical oncology, 2006, Volume: 11, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Design; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Research Design; Trastuzumab

2006
Epidermal growth factor receptor targeting in cancer.
    Seminars in oncology, 2006, Volume: 33, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2006
Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
    ONS news, 2006, Volume: 21, Issue:8 Suppl

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Communication; Cetuximab; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Forecasting; Gefitinib; Humans; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Care Planning; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2006
Protein kinases as drug targets in cancer.
    Current cancer drug targets, 2006, Volume: 6, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzenesulfonates; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Trastuzumab

2006
Growth factor receptor interplay and resistance in cancer.
    Endocrine-related cancer, 2006, Volume: 13 Suppl 1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Binding; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction

2006
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
    Cancer letters, 2007, Sep-08, Volume: 254, Issue:2

    Topics: Antineoplastic Agents; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morphogenesis; Neoplasm Invasiveness; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction

2007
Strategies to optimize the use of targeted agents for tumor therapy.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2008, Volume: 6, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cell Transformation, Neoplastic; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Synergism; Gefitinib; Gene Silencing; Humans; Neoplasms; Prognosis; Quinazolines

2008
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Current medicinal chemistry, 2008, Volume: 15, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab

2008
Commentary: Novel therapies for cancer: why dirty might be better.
    The oncologist, 2008, Volume: 13, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubules; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Purinergic P2

2008
Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.
    Drugs, 2000, Volume: 60 Suppl 1

    Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Gefitinib; Humans; Ligands; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transforming Growth Factor alpha

2000
On receptor inhibitors and chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caenorhabditis elegans Proteins; Cetuximab; ErbB Receptors; Gefitinib; Helminth Proteins; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2

2000
[Zd 1839 "Iressa"].
    Bulletin du cancer, 2000, Volume: 87, Issue:12

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Half-Life; Humans; Mice; Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured

2000
[Tumor angiogenesis and tumor angiogenesis inhibitors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:5

    Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1

2001
[Tyrosine kinase inhibitors--solid cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Enzyme Inhibitors; Gefitinib; Humans; Neoplasm Metastasis; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction

2001
The EGF receptor family as targets for cancer therapy.
    Oncogene, 2000, Dec-27, Volume: 19, Issue:56

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mice; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab

2000
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines; Xenograft Model Antitumor Assays

2001
Tyrosine kinase inhibitors-ZD1839 (Iressa).
    Current opinion in oncology, 2001, Volume: 13, Issue:6

    Topics: Animals; Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials as Topic; Disease Progression; Dogs; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Neoplasms; Quinazolines; Rats

2001
Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
    Seminars in radiation oncology, 2001, Volume: 11, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Signal Transduction

2001
ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
    Expert opinion on investigational drugs, 2002, Volume: 11, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Device Approval; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Signal Transduction

2002

Trials

23 trial(s) available for gefitinib and Neoplasms

ArticleYear
Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study.
    Targeted oncology, 2020, Volume: 15, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prospective Studies

2020
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus

2016
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6

    Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Interactions; Female; Gefitinib; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Quinazolines; Treatment Outcome; Young Adult

2014
Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Adult; Aged; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Pain Measurement; Panitumumab; Prospective Studies; Quinazolines; Recurrence; Young Adult

2015
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
    Investigational new drugs, 2016, Volume: 34, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome

2016
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides

2008
A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2009, Volume: 65, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Calcitriol; Dexamethasone; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Hypercalcemia; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines

2009
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27

    Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Child; Child, Preschool; Drug Synergism; Female; Gefitinib; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Toxicity Tests; Young Adult

2009
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:5

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Therapy, Combination; ErbB Receptors; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Netherlands; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult

2010
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome

2012
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-15, Volume: 20, Issue:18

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases

2002
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Japan; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome

2003
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome

2004
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Investigational new drugs, 2005, Volume: 23, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Canada; ErbB Receptors; Female; Gefitinib; Half-Life; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2005
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-01, Volume: 23, Issue:25

    Topics: Administration, Oral; Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Child, Preschool; ErbB Receptors; Female; Gefitinib; Humans; Infant; Male; Neoplasms; Quinazolines; Treatment Outcome

2005
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Clinical pharmacokinetics, 2005, Volume: 44, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Gefitinib; Humans; Itraconazole; Male; Metoprolol; Microsomes, Liver; Middle Aged; Neoplasms; Quinazolines; Rifampin

2005
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.
    Pediatric blood & cancer, 2007, Volume: 49, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Biomarkers; Child; Child, Preschool; ErbB Receptors; Female; Gefitinib; Humans; Infant; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A

2007
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Taxoids

2007
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
    Journal of the National Cancer Institute, 2006, Dec-06, Volume: 98, Issue:23

    Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Environmental Exposure; ErbB Receptors; Gefitinib; Humans; Neoplasms; Phenotype; Protein Kinase Inhibitors; Quinazolines

2006
A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-15, Volume: 13, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Injections, Intravenous; Male; Middle Aged; Neoplasms; Phosphorylation; Quinazolines

2007
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.
    Clinical & developmental immunology, 2007, Volume: 2007

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Dendritic Cells; Female; Flow Cytometry; Gefitinib; Humans; Male; Middle Aged; Myeloid Cells; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor

2007
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-01, Volume: 20, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Keratinocytes; Male; MAP Kinase Signaling System; Middle Aged; Neoplasms; Quinazolines; Skin; Statistics, Nonparametric; Tumor Suppressor Proteins

2002
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, May-01, Volume: 20, Issue:9

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome

2002

Other Studies

133 other study(ies) available for gefitinib and Neoplasms

ArticleYear
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
    Bioorganic & medicinal chemistry letters, 2006, Sep-15, Volume: 16, Issue:18

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; ErbB Receptors; Fluorine; Gefitinib; Humans; Inhibitory Concentration 50; Mice; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Structure-Activity Relationship; Thiazoles; Xenograft Model Antitumor Assays

2006
Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:7

    Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; ErbB Receptors; Gefitinib; Humans; Models, Molecular; Neoplasms; Phosphotransferases; Protein Structure, Tertiary; Quinazolines

2009
Kinase domain mutations in cancer: implications for small molecule drug design strategies.
    Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6

    Topics: Amino Acid Sequence; Antineoplastic Agents; Drug Design; Enzyme Inhibitors; Humans; Molecular Sequence Data; Mutation; Neoplasms; Phosphotransferases; Protein Conformation

2009
Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
    Bioorganic & medicinal chemistry, 2011, Aug-01, Volume: 19, Issue:15

    Topics: Antineoplastic Agents; Benzimidazoles; Cell Proliferation; Drug Discovery; ErbB Receptors; Hep G2 Cells; Humans; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2

2011
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:10

    Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Oxazines; Structure-Activity Relationship

2011
Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
    Bioorganic & medicinal chemistry, 2013, Nov-01, Volume: 21, Issue:21

    Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dogs; Drug Resistance, Neoplasm; Half-Life; Humans; Madin Darby Canine Kidney Cells; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-met; Pyridines; Rats; Signal Transduction; Structure-Activity Relationship; Sulfonamides; Transplantation, Heterologous

2013
Synthesis and biological evaluation of compounds which contain pyrazole, thiazole and naphthalene ring as antitumor agents.
    Bioorganic & medicinal chemistry letters, 2014, May-15, Volume: 24, Issue:10

    Topics: Antineoplastic Agents; Cell Movement; Cell Proliferation; Humans; Models, Molecular; Naphthalenes; Neoplasms; Pyrazoles; Structure-Activity Relationship; Thiazoles

2014
The discovery of oxazolones-grafted spirooxindoles via three-component diversity oriented synthesis and their preliminary biological evaluation.
    Bioorganic & medicinal chemistry letters, 2015, Sep-01, Volume: 25, Issue:17

    Topics: Antineoplastic Agents; Azo Compounds; Benzylidene Compounds; Cell Line, Tumor; Cycloaddition Reaction; Drug Discovery; Humans; Indoles; Models, Molecular; Neoplasms; Oxazolone; Oxindoles; Pyrrolidines; Spiro Compounds; Stereoisomerism; Thiosemicarbazones

2015
Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK.
    Bioorganic & medicinal chemistry, 2016, 10-01, Volume: 24, Issue:19

    Topics: Antineoplastic Agents; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quantitative Structure-Activity Relationship

2016
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
    Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7

    Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Neoplasms; NF-kappa B; Quinazolines; Signal Transduction; Thiourea

2017
Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors.
    Bioorganic & medicinal chemistry, 2018, 05-01, Volume: 26, Issue:8

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Purines; Structure-Activity Relationship; Transplantation, Heterologous

2018
Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
    European journal of medicinal chemistry, 2018, Aug-05, Volume: 156

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Isatin; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors

2018
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
    Bioorganic & medicinal chemistry, 2018, 09-01, Volume: 26, Issue:16

    Topics: Animals; Antineoplastic Agents; Blood Proteins; Cell Line, Tumor; Cytochrome P-450 Enzyme System; Deuterium; Diketopiperazines; Female; Half-Life; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Neoplasms; Protein Binding; Rats; Rats, Wistar; Tissue Distribution

2018
Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy.
    Bioorganic & medicinal chemistry letters, 2018, 12-15, Volume: 28, Issue:23-24

    Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Drug Design; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 8; Matrix Metalloproteinase Inhibitors; Molecular Docking Simulation; Neoplasms; Pyrazoles; Quantitative Structure-Activity Relationship; Thiazoles

2018
New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors.
    Bioorganic & medicinal chemistry letters, 2019, 10-01, Volume: 29, Issue:19

    Topics: Amides; Antineoplastic Agents; Cell Proliferation; Click Chemistry; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Structure-Activity Relationship; Triazoles

2019
Antiproliferative effect of mitochondria-targeting allobetulin 1,2,3-triazolium salt derivatives and their mechanism of inducing apoptosis of cancer cells.
    European journal of medicinal chemistry, 2020, Dec-01, Volume: 207

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neoplasms; Reactive Oxygen Species; Triazoles

2020
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
    European journal of medicinal chemistry, 2022, Apr-05, Volume: 233

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel

2022
Evaluation of thermosensitive chitosan hydrogel containing gefitinib loaded cellulose acetate butyrate nanoparticles in a subcutaneous breast cancer model.
    International journal of pharmaceutics, 2022, Aug-25, Volume: 624

    Topics: Animals; Butyrates; Cellulose; Chitosan; Drug Carriers; Gefitinib; Hydrogels; Mice; Nanoparticles; Neoplasms; Particle Size

2022
Thermosensitive polymers-based injectable hydrogels: a quantitative validations design utilized for controlled delivery of gefitinib anticancer drug.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:6

    Topics: Animals; Antineoplastic Agents; Chitosan; Gefitinib; Hydrogels; Neoplasms; Poloxamer; Polymers; Rats; Temperature

2023
NAT10-mediated ac4C tRNA modification promotes EGFR mRNA translation and gefitinib resistance in cancer.
    Cell reports, 2023, 07-25, Volume: 42, Issue:7

    Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Mice; N-Terminal Acetyltransferases; Neoplasms; Protein Biosynthesis; RNA, Transfer

2023
Design, synthesis and biological evaluation of small molecule fluorescent probes targeting EGFR for tumor detection and treatment.
    The Analyst, 2023, Dec-04, Volume: 148, Issue:24

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Fluorescent Dyes; Gefitinib; Humans; Lung Neoplasms; Mice; Neoplasms; Quinazolines

2023
Development of amine-functionalized superparamagnetic iron oxide nanoparticles anchored graphene nanosheets as a possible theranostic agent in cancer metastasis.
    Drug delivery and translational research, 2020, Volume: 10, Issue:4

    Topics: Amines; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Liberation; Erythrocytes; Ferric Compounds; Gefitinib; Graphite; Hemolysis; Humans; Magnetic Phenomena; Methylamines; Nanoparticles; Neoplasms

2020
Construction of graphene quantum dots-decorated EGFR cell membrane chromatography for screening active components from Peucedanum praeruptorum Dunn.
    Analytical and bioanalytical chemistry, 2021, Volume: 413, Issue:7

    Topics: Antineoplastic Agents; Apiaceae; Cell Membrane; Chemistry, Pharmaceutical; Chromatography; Drug Design; ErbB Receptors; Gefitinib; Graphite; HEK293 Cells; Humans; Medicine, Chinese Traditional; Microscopy, Electron, Scanning; Molecular Docking Simulation; Neoplasms; Quantum Dots; Silicon Dioxide; Spectroscopy, Fourier Transform Infrared

2021
Circulating Small Extracellular Vesicles Activate TYRO3 to Drive Cancer Metastasis and Chemoresistance.
    Cancer research, 2021, 07-01, Volume: 81, Issue:13

    Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Vesicles; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Receptor Protein-Tyrosine Kinases; Splenic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021
Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
    Oncotarget, 2017, May-23, Volume: 8, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Biomarkers, Tumor; Calcifediol; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Survival Analysis

2017
mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy.
    Journal of nanobiotechnology, 2017, Oct-04, Volume: 15, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Cell Line, Tumor; Chitosan; Chloroquine; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Nanoparticles; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2017
Dielectrophoretic analysis of treated cancer cells for rapid assessment of treatment efficacy.
    Electrophoresis, 2018, Volume: 39, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Electrophoresis; ErbB Receptors; Gefitinib; Humans; Neoplasms; Precision Medicine

2018
High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing.
    Biomaterials, 2019, Volume: 198

    Topics: Animals; Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Screening Assays, Antitumor; Equipment Design; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors

2019
Topical Plant Polyphenols Prevent Type I Interferon Signaling in the Skin and Suppress Contact Hypersensitivity.
    International journal of molecular sciences, 2018, Sep-06, Volume: 19, Issue:9

    Topics: Administration, Topical; Animals; Cells, Cultured; Cetuximab; Chemokine CXCL10; Dermatitis, Allergic Contact; Disease Models, Animal; Gefitinib; Humans; Interferon Regulatory Factor-1; Interferon Type I; Keratinocytes; Mice; Neoplasms; Phosphorylation; Plant Extracts; Polyphenols; Quercetin; Resveratrol; Signal Transduction; STAT1 Transcription Factor

2018
Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand.
    Cell death & disease, 2018, 09-24, Volume: 9, Issue:10

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Ligands; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction; STAT1 Transcription Factor

2018
Synthesis, Characterization, and Biological Activity of a Novel Series of Benzo[4,5]imidazo[2,1-
    Molecules (Basel, Switzerland), 2019, Feb-14, Volume: 24, Issue:4

    Topics: Acetamides; Antineoplastic Agents; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Molecular Docking Simulation; Neoplasms; Thiazoles

2019
Integrin-independent support of cancer drug resistance by tetraspanin CD151.
    Cellular and molecular life sciences : CMLS, 2019, Volume: 76, Issue:8

    Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Integrins; Laminin; Neoplasms; RNA, Messenger; Tetraspanin 24

2019
High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases.
    The oncologist, 2013, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Biopsy; Docetaxel; Female; Gefitinib; Granuloma; Humans; Lung; Male; Middle Aged; Neoplasms; Quinazolines; Retrospective Studies; Taxoids; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed

2013
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.
    Cancer research, 2013, May-15, Volume: 73, Issue:10

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Genotype; Humans; MicroRNAs; Neoplasms; Neoplastic Stem Cells; Quinazolines; Retinal Dehydrogenase; Transcriptome

2013
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
    Cancer discovery, 2013, Volume: 3, Issue:9

    Topics: Animals; Cell Line, Tumor; Dasatinib; ErbB Receptors; Gefitinib; Heterografts; High-Throughput Screening Assays; Humans; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiazoles

2013
Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Quinazolines; Tumor Microenvironment; Xenograft Model Antitumor Assays

2013
The economic evaluation of personalised oncology medicines: ethical challenges.
    The Medical journal of Australia, 2013, Oct-07, Volume: 199, Issue:7

    Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Precision Medicine; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome

2013
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
    Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins

2013
Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.
    BMC cancer, 2013, Nov-06, Volume: 13

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Ki-67 Antigen; Mice; Neoplasms; Phosphorylation; Quinazolines; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays

2013
Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Biomarkers; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Human Umbilical Vein Endothelial Cells; Humans; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Models, Animal; Molecular Imaging; Neoplasm Transplantation; Neoplasms; Optics and Photonics; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Time Factors; Vascular Endothelial Growth Factor A

2014
Clinical trials: More trials, fewer tribulations.
    Nature, 2014, May-29, Volume: 509, Issue:7502

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Crizotinib; DNA Mutational Analysis; Drug Approval; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridines; Quinazolines; Quinolines; Sample Size

2014
More trials, fewer tribulations.
    Scientific American, 2014, Volume: 311, Issue:1

    Topics: Antineoplastic Agents; Bayes Theorem; Clinical Trials as Topic; Drug Approval; Gefitinib; Humans; Mutation; National Cancer Institute (U.S.); Neoplasms; Quinazolines; Transcriptome; United States

2014
ProKinO: a unified resource for mining the cancer kinome.
    Human mutation, 2015, Volume: 36, Issue:2

    Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Data Mining; Gefitinib; Gene Ontology; Humans; Hydrophobic and Hydrophilic Interactions; Knowledge Bases; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sequence Alignment; Software

2015
Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
    Molecular cancer research : MCR, 2015, Volume: 13, Issue:4

    Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Signal Transduction; STAT5 Transcription Factor

2015
Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Animals; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Drug Design; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; src-Family Kinases; Thiazoles; Transplantation, Heterologous

2015
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
    Cancer research, 2015, Aug-15, Volume: 75, Issue:16

    Topics: Aniline Compounds; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HCT116 Cells; HEK293 Cells; Heterocyclic Compounds, 2-Ring; Humans; Models, Molecular; Molecular Structure; Neoplasms; Point Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines

2015
c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.
    Cancer research, 2015, Nov-01, Volume: 75, Issue:21

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-myc; Pyridazines; Quinazolines; RNA Interference; RNA, Small Interfering; Triazoles; Xenograft Model Antitumor Assays

2015
A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans.
    The AAPS journal, 2016, Volume: 18, Issue:1

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Blood Proteins; Gefitinib; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Mice; Models, Statistical; Neoplasms; Pharmacokinetics; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Species Specificity; Tissue Distribution

2016
Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance.
    International journal of nanomedicine, 2015, Volume: 10

    Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Chitosan; Deoxyribonuclease I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Endocytosis; Flow Cytometry; Gefitinib; HeLa Cells; Humans; Intracellular Space; Nanoparticles; Neoplasms; Particle Size; Quinazolines; RNA, Small Interfering; Transfection

2015
Identification of drugs that restore primary cilium expression in cancer cells.
    Oncotarget, 2016, Mar-01, Volume: 7, Issue:9

    Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cilia; Drug Screening Assays, Antitumor; Gefitinib; Humans; Microscopy, Confocal; Neoplasms; Pancreatic Neoplasms; Quinazolines; Reproducibility of Results

2016
Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis.
    The Journal of biological chemistry, 2016, Sep-30, Volume: 291, Issue:40

    Topics: Amphiregulin; beta-Transducin Repeat-Containing Proteins; ErbB Receptors; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; HeLa Cells; Humans; Male; Neoplasms; Quinazolines; Signal Transduction; T-Lymphocytes, Regulatory

2016
Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells.
    Journal of proteome research, 2016, 12-02, Volume: 15, Issue:12

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphopeptides; Protein Kinase Inhibitors; Proteome; Proteomics; Pyridones; Pyrimidinones; Quinazolines

2016
Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.
    BMJ open, 2017, 01-20, Volume: 7, Issue:1

    Topics: Algorithms; Antineoplastic Agents; Bortezomib; Commerce; Cost-Benefit Analysis; Dasatinib; Drug Costs; Drugs, Generic; England; Everolimus; Gefitinib; Humans; Neoplasms; Quinazolines

2017
Mechanisms of resistance to ErbB-targeted cancer therapeutics.
    The Journal of clinical investigation, 2008, Volume: 118, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Mice; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, IGF Type 1; Signal Transduction; Xenograft Model Antitumor Assays

2008
[EGFR and gefitinib (Iressa)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:7

    Topics: Animals; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Quinazolines; Substrate Specificity

2008
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16

    Topics: Aged; Animals; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoprecipitation; Inositol 1,4,5-Trisphosphate Receptors; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Middle Aged; Mitochondria; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiopharmaceuticals; Signal Transduction; Technetium Tc 99m Sestamibi

2008
Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    International journal of cancer, 2008, Dec-15, Volume: 123, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Cyclin D1; DNA, Complementary; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Repressor Proteins; RNA, Small Interfering; Sequence Analysis, DNA; Signal Transduction

2008
Pharmaceutical futures: a fiendish puzzle.
    Nature, 2008, Oct-30, Volume: 455, Issue:7217

    Topics: Animals; Clinical Trials as Topic; Computer Simulation; Diabetes Mellitus, Type 2; Drug Industry; Gefitinib; Genomics; Glycoproteins; Humans; Models, Biological; Neoplasms; Proteome; Quinazolines; Systems Biology

2008
Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.
    Cancer investigation, 2009, Volume: 27, Issue:2

    Topics: Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Survival; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases

2009
Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.
    Anticancer research, 2009, Volume: 29, Issue:4

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Cells, Cultured

2009
Predicting differences in gene regulatory systems by state space models.
    Genome informatics. International Conference on Genome Informatics, 2008, Volume: 21

    Topics: Antineoplastic Agents; Case-Control Studies; Epithelial Cells; ErbB Receptors; Gefitinib; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genes, Regulator; Humans; Models, Genetic; Neoplasms; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Neoplasms

2008
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
    Journal of receptor and signal transduction research, 2009, Volume: 29, Issue:3-4

    Topics: Antineoplastic Agents; Biosensing Techniques; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2009
The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro.
    Journal of experimental & clinical cancer research : CR, 2009, Sep-01, Volume: 28

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasms; PTEN Phosphohydrolase; Quinazolines; Up-Regulation; X-Rays

2009
New frontiers in biomarker-targeted molecular imaging.
    Cancer biology & therapy, 2009, Volume: 8, Issue:23

    Topics: Animals; ErbB Receptors; Gefitinib; Humans; Molecular Imaging; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Xenograft Model Antitumor Assays

2009
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
    Cancer research, 2010, Mar-15, Volume: 70, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cetuximab; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Gefitinib; Humans; Ligands; Mice; Neoplasms; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Xenograft Model Antitumor Assays

2010
Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:11

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Diarrhea; Drug Eruptions; ErbB Receptors; Exanthema; Gefitinib; Germ-Line Mutation; Humans; Infant; Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Young Adult

2010
A novel hybrid peptide targeting EGFR-expressing cancers.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:5

    Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Mutant Chimeric Proteins; Neoplasm Transplantation; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous

2011
Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.
    Anticancer research, 2010, Volume: 30, Issue:12

    Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Melanoma; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2010
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
    Cancer cell, 2011, Jan-18, Volume: 19, Issue:1

    Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays

2011
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:8

    Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline

2012
Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
    Molecular & cellular proteomics : MCP, 2012, Volume: 11, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Chromatography, Liquid; Colorectal Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gastritis, Hypertrophic; Gefitinib; Humans; Mice; Neoplasms; Neoplasms, Glandular and Epithelial; Phosphorylation; Prospective Studies; Proteomics; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transplantation, Heterologous

2012
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
    The pharmacogenomics journal, 2013, Volume: 13, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Association Studies; Haplotypes; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines

2013
Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Ascorbic Acid; Cell Death; Cell Line, Tumor; Computer Simulation; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Silencing; Humans; Models, Biological; Neoplasms; Oncogenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Reproducibility of Results; Signal Transduction; Systems Biology

2011
Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.
    Cell, 2012, May-11, Volume: 149, Issue:4

    Topics: Amino Acid Sequence; Crystallography, X-Ray; ErbB Receptors; Gefitinib; Humans; Lapatinib; Molecular Dynamics Simulation; Molecular Sequence Data; Neoplasms; Point Mutation; Protein Folding; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Tertiary; Quinazolines; Sequence Alignment; Signal Transduction

2012
Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.
    Journal of pharmaceutical sciences, 2012, Volume: 101, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liposomes; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Spectrometry, Fluorescence

2012
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Chicago; ErbB Receptors; Erlotinib Hydrochloride; Eye Diseases; Female; Follow-Up Studies; Gefitinib; Humans; Male; Medical Audit; Neoplasms; Panitumumab; Quinazolines; Retrospective Studies

2013
Cancer drugs. Smart weapons prove tough to design.
    Science (New York, N.Y.), 2002, Oct-18, Volume: 298, Issue:5593

    Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration

2002
The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Nov-01, Volume: 20, Issue:21

    Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Endpoint Determination; Gefitinib; Humans; Interprofessional Relations; Multicenter Studies as Topic; Neoplasms; Physician's Role; Quinazolines; Research Design

2002
Synthetic lethality: killing cancer with cancer.
    Journal of the National Cancer Institute, 2002, Nov-20, Volume: 94, Issue:22

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; Gefitinib; Genes, Tumor Suppressor; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mutation; Neoplasms; Phosphoric Monoester Hydrolases; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Signal Transduction; Sirolimus; Transcription Factors; Tumor Suppressor Proteins

2002
Demand grows for early access to promising cancer drugs.
    Journal of the National Cancer Institute, 2002, Nov-20, Volume: 94, Issue:22

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Approval; Drug Costs; Drugs, Investigational; Gefitinib; Health Services Accessibility; Humans; Lung Neoplasms; Neoplasms; Patient Advocacy; Quinazolines; United States; United States Food and Drug Administration

2002
On target. A new generation of drugs offers customized cures.
    U.S. news & world report, 2003, Jan-20, Volume: 134, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Delivery Systems; Drug Design; Enzyme Inhibitors; Female; Gefitinib; Humans; Male; Neoplasms; Pharmacogenetics; Quinazolines; Receptors, Growth Factor; Trastuzumab; United States

2003
Apparent adverse drug reactions prompt concern about Iressa.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Japan; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; United States; United States Food and Drug Administration

2003
Signal transduction modulators for cancer therapy: from promise to practice?
    The oncologist, 2003, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Health Knowledge, Attitudes, Practice; Humans; Neoplasms; Quinazolines; Signal Transduction; United States; Vascular Endothelial Growth Factor Receptor-2

2003
Selection bias, phase II trials, and the FDA accelerated approval process.
    Journal of the National Cancer Institute, 2003, Sep-17, Volume: 95, Issue:18

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Quinazolines; Selection Bias; Treatment Outcome; United States; United States Food and Drug Administration

2003
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-01, Volume: 9, Issue:10 Pt 1

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Radiation; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Time Factors

2003
Combinations of targeted therapies take aim at multiple pathways.
    Journal of the National Cancer Institute, 2003, Nov-19, Volume: 95, Issue:22

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Research Design

2003
[Targeted molecular therapy: the example of Iressa (ZD1839)].
    Medecine sciences : M/S, 2003, Volume: 19, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines

2003
Novel cancer therapies: targeting the molecules.
    JAAPA : official journal of the American Academy of Physician Assistants, 2003, Volume: 16, Issue:10

    Topics: Alkyl and Aryl Transferases; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Delivery Systems; Farnesyltranstransferase; Gefitinib; Humans; Lymphoma, B-Cell; Medical Oncology; Neoplasms; Quinazolines; Rituximab

2003
Protein kinase inhibitors: novel tools in cancer therapy.
    Der Urologe. Ausg. A, 2004, Volume: 43 Suppl 3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Transformation, Neoplastic; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Signal Transduction

2004
New cancer therapeutics: target-specific in, cytotoxics out?
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2004, Volume: 7, Issue:2

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Proteomics; Pyrroles; Quinazolines; Sunitinib

2004
Look before you leap.
    Nature medicine, 2004, Volume: 10, Issue:6

    Topics: Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Neoplasms; Patient Selection; Quinazolines

2004
An image worth a thousand lives?
    Nature biotechnology, 2004, Volume: 22, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzoquinones; Bibenzyls; Diagnostic Imaging; Down-Regulation; ErbB Receptors; Gefitinib; Heterocyclic Compounds, 1-Ring; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Magnetic Resonance Imaging; Molecular Probe Techniques; Mutation; Neoplasms; Phthalazines; Physiological Phenomena; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Rifabutin; Stilbenes; Tissue Distribution; Trastuzumab

2004
Imatinib: paradigm or anomaly?
    Cell cycle (Georgetown, Tex.), 2004, Volume: 3, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Early Diagnosis; Gefitinib; Humans; Imatinib Mesylate; Mutation; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Receptors, Growth Factor; Signal Transduction

2004
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
    The British journal of dermatology, 2004, Volume: 151, Issue:1

    Topics: Acneiform Eruptions; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines

2004
[Target molecules of molecular target therapy of cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Delivery Systems; Gefitinib; Molecular Chaperones; Neoplasms; Quinazolines; Rituximab; Trastuzumab

2004
Lung cancer: intragenic ERBB2 kinase mutations in tumours.
    Nature, 2004, Sep-30, Volume: 431, Issue:7008

    Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation; Neoplasms; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2

2004
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
    BMC cancer, 2004, Nov-23, Volume: 4

    Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms

2004
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.
    Cancer research, 2004, Dec-15, Volume: 64, Issue:24

    Topics: Base Sequence; Cell Line, Tumor; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; Molecular Sequence Data; Neoplasms; Piperidines; Quinazolines; Transfection; Vascular Endothelial Growth Factor Receptor-2

2004
[Targeted drugs in radiation therapy].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8 Suppl 1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Mice; Mice, Nude; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Trastuzumab; Tumor Cells, Cultured

2004
Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:4

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Models, Chemical; Mutation; Neoplasm Transplantation; Neoplasms; Quinazolines; Rats; Rats, Nude; Scintillation Counting; Signal Transduction; Time Factors; Tissue Distribution

2005
Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.
    Onkologie, 2005, Volume: 28, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Lethal Dose 50; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines

2005
Advances in radiosensitization.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Flucytosine; Fluorouracil; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Trastuzumab

2004
[Cutaneous side effects of EGF-receptor inhibition and their management].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2006, Volume: 57, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic

2006
Drug discovery: playing dirty.
    Nature, 2005, Oct-13, Volume: 437, Issue:7061

    Topics: Animals; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Depression; Drug Approval; Drug Design; Drug Evaluation, Preclinical; Drug Industry; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Sensitivity and Specificity; Substrate Specificity; Therapeutics; United States; United States Food and Drug Administration

2005
Epidermal growth factor receptor inhibitors: a moving target?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-15, Volume: 11, Issue:20

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2005
[Current status and prospect of neoplasm targeted therapy].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Design; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Immunologic Factors; Neoplasms; Palliative Care; Piperazines; Pyrimidines; Quinazolines; Signal Transduction

2005
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
    Cancer research, 2006, Feb-15, Volume: 66, Issue:4

    Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, fos; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays

2006
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:2

    Topics: Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Cisplatin; Cytosol; DNA; DNA-Activated Protein Kinase; ErbB Receptors; Etoposide; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; RNA, Small Interfering; Wortmannin

2006
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-01, Volume: 12, Issue:5

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Thiazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2006
What's the rush? The dissemination and adoption of preliminary research results.
    Journal of the National Cancer Institute, 2006, Mar-15, Volume: 98, Issue:6

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Congresses as Topic; Diffusion of Innovation; Evidence-Based Medicine; Female; Gefitinib; Humans; Information Dissemination; Lung Neoplasms; Multicenter Studies as Topic; Neoplasms; Practice Patterns, Physicians'; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United States

2006
Expect the unexpected.
    The Lancet. Oncology, 2006, Volume: 7, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Gefitinib; Heart Diseases; Humans; Multiple Organ Failure; Neoplasms; Pneumonia; Quinazolines

2006
Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.
    Nature medicine, 2006, Volume: 12, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Keratinocytes; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Morphogenesis; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin

2006
Canonical WNT signaling pathway and human AREG.
    International journal of molecular medicine, 2006, Volume: 17, Issue:6

    Topics: Amino Acid Sequence; Amphiregulin; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Computational Biology; Drug Resistance, Neoplasm; EGF Family of Proteins; Gefitinib; Gene Expression Profiling; Genomics; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Molecular Sequence Data; Neoplasms; Pan troglodytes; Phylogeny; Promoter Regions, Genetic; Quinazolines; Signal Transduction; TCF Transcription Factors; Wnt Proteins

2006
Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
    Bioorganic & medicinal chemistry letters, 2006, Aug-01, Volume: 16, Issue:15

    Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Neoplasms; Positron-Emission Tomography; Quinazolines

2006
Impact of genetic diagnostics on drug development strategy.
    Nature reviews. Drug discovery, 2006, Volume: 5, Issue:6

    Topics: Antineoplastic Agents; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Gefitinib; Genetic Testing; Humans; Neoplasms; Pharmacogenetics; Pyrimidines; Quinazolines; Thiazoles

2006
Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-20, Volume: 24, Issue:15

    Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasms; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines

2006
Pharmacy benefit spending on oral chemotherapy drugs.
    Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:7

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States

2006
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
    Journal of the National Cancer Institute, 2006, Dec-06, Volume: 98, Issue:23

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Diarrhea; ErbB Receptors; Gefitinib; Genetic Variation; Humans; Neoplasm Proteins; Neoplasms; Polymorphism, Genetic; Quinazolines; Skin

2006
[International clinical trials for a medical oncologist in Japan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:2

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Gefitinib; Humans; International Cooperation; Japan; Medical Oncology; Neoplasms; Quinazolines; Workforce

2007
New insights into oncogene addiction found.
    Journal of the National Cancer Institute, 2007, Feb-21, Volume: 99, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab

2007
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
    Cancer biology & therapy, 2007, Volume: 6, Issue:3

    Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2007
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.
    Human mutation, 2007, Volume: 28, Issue:8

    Topics: Adult; Aged; Base Sequence; Cluster Analysis; Databases, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutagenesis, Insertional; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines; Sequence Deletion; Smoking

2007
Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells.
    Proteomics, 2007, Volume: 7, Issue:14

    Topics: Amino Acid Sequence; Cell Line, Tumor; Epidermal Growth Factor; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Microtubule-Associated Proteins; Molecular Sequence Data; Neoplasms; Phosphoproteins; Phosphotyrosine; Proteomics; Quinazolines; Serine Endopeptidases; Signal Transduction; Tandem Mass Spectrometry

2007
Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Breast cancer research and treatment, 2008, Volume: 111, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Insulin Receptor Substrate Proteins; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Cross-Talk; Receptors, Somatomedin; Signal Transduction

2008
Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines.
    Cancer letters, 2007, Nov-18, Volume: 257, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Biological Transport; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Gefitinib; Glucose; Glucose Transporter Type 1; Humans; Neoplasms; Paclitaxel; Quinazolines

2007
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Cancer research, 2007, Nov-15, Volume: 67, Issue:22

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estradiol; Gefitinib; Humans; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Binding; Quinazolines

2007
Analysis of duration of response in oncology trials.
    Contemporary clinical trials, 2008, Volume: 29, Issue:4

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytotoxins; Data Interpretation, Statistical; Gefitinib; Humans; Models, Theoretical; Neoplasms; Prognosis; Quinazolines; Time Factors; Treatment Outcome

2008
Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:6

    Topics: Animals; Cell Line, Tumor; Chlorocebus aethiops; ErbB Receptors; Fluorine Radioisotopes; Gefitinib; Metabolic Clearance Rate; Mice; Molecular Probe Techniques; Neoplasms; Organ Specificity; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution

2008
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.
    British journal of cancer, 2008, Mar-11, Volume: 98, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Endothelial Cells; ErbB Receptors; Everolimus; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neovascularization, Physiologic; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Transplantation, Heterologous

2008
Epidermal growth factor receptor inhibitors and hair.
    Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair; Humans; Neoplasms; Quinazolines

2008
Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials.
    Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines

2001
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
    International journal of cancer, 2002, Mar-10, Volume: 98, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; K562 Cells; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Phosphorylation; Quinazolines; RNA, Neoplasm; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured

2002
Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, May-01, Volume: 20, Issue:9

    Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Protein-Tyrosine Kinases; Quinazolines

2002
chemdatabank.com